In this study, we develop for the first time a CRISPR/Cas9@PDA nano-delivery system that can achieve high-efficiency delivery of CRISPR/Cas9-3NLS/sgHMGA2 and high-efficiency HMGA2 gene editing of gastric cancer (Figure 1). This evidence concerns the gene HMGA2 and gastric cancer.